Suggested remit: To appraise the clinical and cost effectiveness of niraparib within its marketing authorisation as maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after complete or partial response to first-line platinum-based chemotherapy.
 
Status In progress
Process STA 2018
ID number 1680

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 12 November 2019 - 10 December 2019

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
18 March 2019 In progress, DHSC Referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance